Kratom is not detected in standard 5-panel drug tests. However, some employers and organizations use more comprehensive drug testing panels that can identify kratom compounds.

CBDVA has an extra carboxyl group, which makes it less bioactive in its raw form than CBDV. Conversely, CBDV is the active form, allowing it to interact more readily with the endocannabinoid system. That said, neither compound significantly affects the ECS. Both are non-psychoactive and may exhibit similar therapeutic potential through their anti-inflammatory properties. However, CBDVA research is scant and limited to preclinical studies.

CBDV is a homolog of CBD, meaning it shares a similar chemical structure but has distinct differences that lead to varied effects and applications. Both CBDV and CBD are non-psychoactive cannabinoids and have been studied for their potential therapeutic applications, including anti-inflammatory, anti-convulsant, and anti-anxiety properties. However, research on CBDV is far less extensive than that on CBD.

Clinical trials have proven CBD’s anti-seizure capabilities, leading to the FDA-approved drug Epidiolex. Conversely, CBDV has yet to pass the FDA approval threshold for medicinal applications. Despite its potential, CBDV remains under-researched compared to its more widely studied counterpart, CBD.

‍

CBN is very similar to CBD in its chemical structure and therapeutic profile. Still, it has essential distinctions in how it occurs and its potential for mild psychoactive effects.

‍

• CBN primarily forms as THC ages, resulting in mild psychoactive effects, unlike CBD, which is non-psychoactive.
• CBN binds weakly to CB1 receptors, contributing to its sedative properties and making it potentially useful for sleep disorders. CBD does not bind with CB1 receptors.

‍

Both cannabinoids show anti-inflammatory and analgesic effects, but CBN has unique antibacterial properties and may stimulate appetite. CBD, on the other hand, is more widely researched for anxiety, epilepsy, and neuroprotection, highlighting its broader therapeutic potential.

‍

CBNA is the acidic version of CBN. Hemp and cannabis plants do not directly synthesize CBNA. Instead, it forms when another compound called tetrahydrocannabinolic acid (THCA) breaks down over time. This breakdown happens due to exposure to air (oxygen) or sunlight (UV light), a process known as oxidative degradation.

Very little research has been conducted on CBNA. However, one in-silico docking study found that CBNA contains antibacterial properties similar to CBN. The study explored how CBNA can inhibit a specific enzyme (TrpE) essential for the bacteria that causes tuberculosis. By targeting this enzyme, CBNA, along with CBGA, could help fight TB, especially in cases where the bacteria have become resistant to existing drugs.

‍

CBC and CBD are both non-psychoactive cannabinoids found in the cannabis plant, each with unique properties and potential therapeutic benefits. CBC interacts primarily with the TRPV1 and TRPA1 receptors, which affect pain perception and inflammation. 

In contrast, CBD has a broader mechanism of action. It interacts with several receptor systems, including the 5-HT1A serotonin receptor, which contributes to its anxiolytic (anxiety-reducing) effects, and the GPR55 receptor, which may regulate blood pressure and bone density. 

CBD is well-known for its anti-inflammatory, analgesic, and antiepileptic properties. It also modulates the endocannabinoid system by inhibiting the enzyme FAAH, which breaks down anandamide, thereby increasing its levels and enhancing its mood-stabilizing effects .